While the risk is small, spotting symptoms early can make a big difference in outcomes.
Just take a little pill…
A recent study of nearly 400,000 patients found that people with attention-deficit/hyperactivity disorder (ADHD) who take stimulants face a small but notable risk of developing psychosis or bipolar disorder. About 3 percent of patients developed one of these conditions after starting medication.
Key Findings
The meta-analysis, published in JAMA Psychiatry, pooled results from 16 studies across North America, Europe, and Asia. It was the first-ever systematic analysis looking at both psychosis and bipolar disorder in relation to ADHD medications.
The study reviewed both amphetamines and methylphenidate, two common stimulant drugs used to treat ADHD. Amphetamines were associated with roughly 60 percent higher odds of developing psychotic symptoms compared with methylphenidate.
On average, stimulant treatment was linked with psychotic symptoms in 3 percent of patients and bipolar disorder in 4 percent.
The studies did not establish baseline rates of these conditions in untreated ADHD patients, making it difficult to determine how much of the observed risk stems from the medications versus the underlying disorder.
Despite the findings, researchers emphasized that stimulants should remain the first-line treatment for most patients, but called for better patient education and monitoring.
Possible Driving Factors
Another meta-analysis found that children with ADHD have nearly a fivefold risk of developing psychosis later in life compared with the general population. They also have a higher risk of bipolar disorder.
At the brain chemistry level, ADHD, psychosis, and bipolar disorder all involve disruptions in the same neurotransmitter – dopamine. Stimulants increase dopamine levels, which is also associated with psychosis and bipolar risk.
Psychosis and bipolar disorder are often linked to high dopamine activity. While people with ADHD often have low dopamine levels, stimulants raise those levels.
Psychosis risk was highest in the United States, where amphetamines such as Adderall and Vyvanse are the first-line treatment for ADHD. Amphetamines are associated with a higher risk of psychosis and mania than methylphenidate because they trigger a much greater dopamine surge – up to four times more.
In contrast, methylphenidate is the first-line choice across much of Europe, where the studies in the review reported much lower rates of psychosis.
Misusing amphetamines by taking doses that are too high can also trigger psychosis or mania. A 2024 Harvard-led study found that high doses of amphetamines (more than 30 milligrams of dextroamphetamine, or roughly 40 milligrams of Adderall) were associated with more than a fivefold increase in risk of psychosis or mania.
Dr. Sharon Batista, an assistant clinical professor of psychiatry at Mount Sinai Hospital, told The Epoch Times that symptoms of stimulant-induced psychosis tend to emerge soon after starting or increasing a dose.
“Families and clinicians should be vigilant for new-onset hallucinations, paranoia, or extreme mood elevation,” she said. “These are red flags that require immediate medical attention.”
Bipolar disorder, psychosis, and ADHD also share similar symptoms such as mood swings, poor sleep, and distractibility.
“Misdiagnosis can lead to inappropriate treatment, so careful evaluation is essential,” Batista said.
Weighing Risks and Benefits
The authors said their findings should not change current guidelines recommending stimulants as first-line treatment for ADHD. However, they stressed the importance of educating patients and families, monitoring closely, and discussing management strategies.
“Like all medicines, stimulants come with side effects. This also includes the risk of developing mania and psychosis,” Dr. Cooper Stone, a clinical assistant professor of psychiatry and behavioral science at the University of Pennsylvania, told The Epoch Times.
He emphasized the importance of discussing these potential side effects with patients before starting treatment so they can make an informed decision. “While stimulants can be tremendously beneficial in those with ADHD, it’s also not a decision to take lightly.”
Most people without an underlying risk for psychosis or bipolar disorder are unlikely to develop these conditions if they take the medication as prescribed and avoid misuse, such as very high doses or nonoral methods.
Practical Steps for Patients and Families
It may be impractical for clinicians to warn every patient about these rare risks – stimulant-induced psychosis or mania occurs in fewer than 1 in 600 patients – or to review every unlikely side effect with all patients.
However, Batista emphasized that it’s important to do so for those at higher risk. “If there is a personal or family history of bipolar disorder or psychosis, we specifically address these risks and monitor closely,” she said.
Stone noted that on the most basic level, clinicians and family members can recognize any concerning changes in a person’s baseline behavior.
He added that symptoms of mania or psychosis often stand out sharply from a patient’s usual behavior, making it clear when something is wrong. Families may not know exactly what is happening, but they can recognize that the person is unwell – and that is the signal to seek medical help right away.
Patients and families can work with clinicians to reduce risk and spot problems early. Here are some tips from the study’s authors and Stone:
* Ask Before Starting: Check whether your clinician has reviewed your family history of psychosis or bipolar disorder.
* Start Low, Go Slow: Increase doses gradually, especially with amphetamines.
* Watch for Changes: Monitor for unusual thoughts, paranoia, or sudden mood shifts—stop the medication and call your doctor if they occur.
* Know Your Options: Choose nonstimulant alternatives such as atomoxetine if stimulants are not tolerated; these carry no evidence of psychosis risk.
* Consider Behavioral Therapy: Use cognitive behavioral therapy targeting executive function to help manage ADHD symptoms.
Written by Rachel Ann T. Melegrito for Epoch Health ~ September 28, 2025